Insurance companies end up covering proton therapy treatment for pediatric cancer patients in 97 percent of the cases they originally deny once those decisions are appealed. Researchers analyzed five years of coverage decisions at Penn’s Roberts Proton Therapy Center. They discovered that roughly one in 10 pediatric cancer patients are initially denied coverage for the cutting edge and costly treatment – yet nearly all patients ultimately get approval.